Importantly, a DNAM-1 and NKp30 blockade reduced the lysis of cancer target cells, and together the two blocking antibodies displayed a synergistic effect that abrogates NK cell-mediated killing of U87 cells pre-sensitized via treatment with MHT. This evidence concerns the gene CD226 and cancer.